Services Agreement: Citn-12: Phase I Study Of Mk-3475 (Pembrolizumab) In Patients With Human Immunodeficiency Virus (Hiv) And Relapsed/Refractory Or Disseminated Malignant Neoplasm (Clinical Trial)